Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Glucosylceramidase (Acid Beta Glucosidase or Alglucerase or D Glucosyl N Acylsphingosine Glucohydrolase or Beta Glucocerebrosidase or Imiglucerase or GBA or EC 3.2.1.45) Overview | 7 | 1 |
| Therapeutics Development | 8 | 3 |
| Glucosylceramidase (Acid Beta Glucosidase or Alglucerase or D Glucosyl N Acylsphingosine Glucohydrolase or Beta Glucocerebrosidase or Imiglucerase or GBA or EC 3.2.1.45) Products under Development by Stage of Development | 8 | 1 |
| Glucosylceramidase (Acid Beta Glucosidase or Alglucerase or D Glucosyl N Acylsphingosine Glucohydrolase or Beta Glucocerebrosidase or Imiglucerase or GBA or EC 3.2.1.45) Products under Development by Therapy Area | 9 | 1 |
| Glucosylceramidase (Acid Beta Glucosidase or Alglucerase or D Glucosyl N Acylsphingosine Glucohydrolase or Beta Glucocerebrosidase or Imiglucerase or GBA or EC 3.2.1.45) Products under Development by Indication | 10 | 1 |
| Glucosylceramidase (Acid Beta Glucosidase or Alglucerase or D Glucosyl N Acylsphingosine Glucohydrolase or Beta Glucocerebrosidase or Imiglucerase or GBA or EC 3.2.1.45) Pipeline Products Glance | 11 | 2 |
| Late Stage Products | 11 | 1 |
| Early Stage Products | 12 | 1 |
| Glucosylceramidase (Acid Beta Glucosidase or Alglucerase or D Glucosyl N Acylsphingosine Glucohydrolase or Beta Glucocerebrosidase or Imiglucerase or GBA or EC 3.2.1.45) Products under Development by Companies | 13 | 2 |
| Glucosylceramidase (Acid Beta Glucosidase or Alglucerase or D Glucosyl N Acylsphingosine Glucohydrolase or Beta Glucocerebrosidase or Imiglucerase or GBA or EC 3.2.1.45) Products under Development by Universities/Institutes | 15 | 2 |
| Glucosylceramidase (Acid Beta Glucosidase or Alglucerase or D Glucosyl N Acylsphingosine Glucohydrolase or Beta Glucocerebrosidase or Imiglucerase or GBA or EC 3.2.1.45) Therapeutics Assessment | 17 | 7 |
| Assessment by Monotherapy/Combination Products | 17 | 1 |
| Assessment by Mechanism of Action | 18 | 2 |
| Assessment by Route of Administration | 20 | 2 |
| Assessment by Molecule Type | 22 | 2 |
| Glucosylceramidase (Acid Beta Glucosidase or Alglucerase or D Glucosyl N Acylsphingosine Glucohydrolase or Beta Glucocerebrosidase or Imiglucerase or GBA or EC 3.2.1.45) Companies Involved in Therapeutics Development | 24 | 7 |
| Greenovation Biotech GmbH | 24 | 1 |
| JCR Pharmaceuticals Co., Ltd. | 25 | 1 |
| Lysosomal Therapeutics Inc. | 26 | 1 |
| Pharming Group N.V. | 27 | 1 |
| Protalix BioTherapeutics, Inc. | 28 | 1 |
| Shire Plc | 29 | 1 |
| The International Biotechnology Center (IBC) Generium | 30 | 1 |
| Glucosylceramidase (Acid Beta Glucosidase or Alglucerase or D Glucosyl N Acylsphingosine Glucohydrolase or Beta Glucocerebrosidase or Imiglucerase or GBA or EC 3.2.1.45) Drug Profiles | 31 | 19 |
| ADN-LYS Drug Profile | 31 | 1 |
| ambroxol Drug Profile | 32 | 2 |
| imiglucerase biosimilar Drug Profile | 34 | 1 |
| MOSS-GBA Drug Profile | 35 | 1 |
| NCGC-607 Drug Profile | 36 | 1 |
| PRX-112 Drug Profile | 37 | 2 |
| Recombinant Beta-Cerebrosidase Replacement for Gaucher's Disease Drug Profile | 39 | 1 |
| Small Molecule to Activate Glucocerebrosidase for Parkinson's, Gaucher's and Neurodegenerative Diseases Drug Profile | 40 | 1 |
| Small Molecules to Activate GCase for Parkinson's Disease Drug Profile | 41 | 1 |
| taliglucerase alfa Drug Profile | 42 | 6 |
| taliglucerase alfa Drug Profile | 48 | 1 |
| velaglucerase alfa Drug Profile | 49 | 1 |
| Glucosylceramidase (Acid Beta Glucosidase or Alglucerase or D Glucosyl N Acylsphingosine Glucohydrolase or Beta Glucocerebrosidase or Imiglucerase or GBA or EC 3.2.1.45) Dormant Projects | 50 | 2 |
| Glucosylceramidase (Acid Beta Glucosidase or Alglucerase or D Glucosyl N Acylsphingosine Glucohydrolase or Beta Glucocerebrosidase or Imiglucerase or GBA or EC 3.2.1.45) Discontinued Products | 52 | 1 |
| Glucosylceramidase (Acid Beta Glucosidase or Alglucerase or D Glucosyl N Acylsphingosine Glucohydrolase or Beta Glucocerebrosidase or Imiglucerase or GBA or EC 3.2.1.45) Featured News &Press Releases | 53 | 11 |
| Feb 12, 2015: Safety and Efficacy of ELELYSO (taliglucerase alfa) for Injection in Pediatric Patients with Type 1 Gaucher Disease in Long-term Outcome Study Presented at the WORLDSymposium 2015 | 53 | 1 |
| Sep 02, 2014: Shire s VPRIV400 units/vial launched in Japan for the improvement of symptoms of Gaucher disease | 53 | 1 |
| Aug 28, 2014: Pfizer and Protalix BioTherapeutics Announce FDA Approval of Pediatric Indication for ELELYSO (taliglucerase alfa) for Injection, for Intravenous Use for the Treatment of Type 1 Gaucher Disease | 54 | 1 |
| Jul 04, 2014: Shire s VPRIV approved in Japan for the improvement of symptoms of Gaucher disease | 55 | 1 |
| Jul 01, 2014: Pfizer Receives Kosher Certification for Elelyso (taliglucerase alfa) for Injection, for the Treatment of Type 1 Gaucher Disease | 56 | 1 |
| Jun 27, 2014: Protalix Announces New Data on ELELYSO (taliglucerase alfa) Presented at the European Working Group on Gaucher Disease 2014 11th Meeting | 56 | 1 |
| Jun 23, 2014: Protalix BioTherapeutics Announces New Data on ELELYSO (taliglucerase alfa) and Oral GCD to be Presented at the European Working Group on Gaucher Disease 2014 11th Meeting | 57 | 1 |
| Jun 18, 2014: Protalix BioTherapeutics Initiates Phase II Study With PRX-112, an Orally-Administered Enzyme Replacement Therapy for the Treatment of Gaucher Disease | 58 | 1 |
| May 30, 2014: Protalix Announces ELELYSO (taliglucerase alfa) Approved in Canada for the Treatment of Gaucher Disease in Both Adult and Pediatric Patients | 58 | 1 |
| May 22, 2014: Protalix Announces ELELYSO Approved in Australia for the Treatment of Gaucher Disease in Both Adult and Pediatric Patients | 59 | 1 |
| Mar 14, 2014: Shire Pharmaceuticals Initiates Voluntary Nationwide Recall Of One Batch, Packaged into Three Lots, of VPRIV (velaglucerase alfa for injection) | 59 | 1 |
| Feb 14, 2014: Shire Announces FDA Approval of Manufacturing Facility for VPRIV (Velaglucerase Alfa for Injection) Drug Substance | 60 | 1 |
| Feb 12, 2014: Protalix BioTherapeutics Announces Oral GCD Data to be Presented at WORLD Symposium 2014 | 61 | 1 |
| Feb 06, 2014: Protalix BioTherapeutics' Technology Transfer Agreement for UPLYSO (alfataliglicerase) With Brazil's Ministry of Health Approved by the Brazilian National Institute of Industrial Property | 62 | 1 |
| Oct 14, 2013: Protalix BioTherapeutics Announces Positive Phase I Clinical Trial Results for Oral GCD in Gaucher Disease Patients | 62 | 2 |
| Appendix | 64 | 2 |
| Methodology | 64 | 1 |
| Coverage | 64 | 1 |
| Secondary Research | 64 | 1 |
| Primary Research | 64 | 1 |
| Expert Panel Validation | 64 | 1 |
| Contact Us | 64 | 1 |
| Disclaimer | 65 | 1 |
